Pictilisib (GDC-0941)

Catalog No.S1065

Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Phase 2.

Price Stock Quantity  
USD 240 In stock
USD 120 In stock
USD 170 In stock
USD 370 In stock
USD 970 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Pictilisib (GDC-0941) Chemical Structure

Pictilisib (GDC-0941) Chemical Structure
Molecular Weight: 513.64

Validation & Quality Control

Cited by 57 publications:

7 customer reviews :

Quality Control & MSDS

Related Compound Libraries

Pictilisib (GDC-0941) is available in the following compound libraries:

PI3K Inhibitors with Unique Features

  • Pan PI3K Inhibitor

    LY294002 Pan-PI3Kα/δ/β inhibitor, IC50=0.5 μM/0.57 μM/0.97 μM.

  • Most Potent PI3K Inhibitor

    Duvelisib (IPI-145, INK1197) PI3K δ, IC50=1 nM.

  • FDA-approved PI3K Inhibitor

    CAL-101 (Idelalisib, GS-1101) Approved by FDA for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma.

  • Newest PI3K Inhibitor

    GSK2636771 Potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines.

Product Information

  • Compare PI3K
    Compare PI3K Products
  • Research Area
  • Inhibition Profile
  • Pictilisib (GDC-0941) Mechanism
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Phase 2.
Targets p110α [1]
(Cell-free assay)
p110δ [1]
(Cell-free assay)
p110β [1]
(Cell-free assay)
p110γ [1]
(Cell-free assay)

 View  More

IC50 3 nM 3 nM 33 nM 75 nM
In vitro GDC-0941 is equipotent against PI3Kα and PI3Kδ as well as PI3Kα mutants E545-K and H1047-R, displaying modest levels of selectivity against PI3Kβ (10-fold) and PI3Kγ (25-fold), and greater levels of selectivity against members of PI3K class II, III, and IV, including C2β, Vps34, DNA-PK, and mTOR. GDC-0941 potently inhibits the phosphorylation of Akt in U87MG, PC3, and MDA-MB-361 cells with IC50 of 46 nM, 37 nM, and 28 nM, respectively. GDC-0941 inhibits the proliferation of U87MG, A2780, PC3, and MDA-MB-361 cells with IC50 of 0.95 μM, 0.14 μM, 0.28 μM, and 0.72 μM, respectively. [1] GDC-0941 treatment potently inhibits the proliferation of both trastuzumab-sensitive and -insensitive HER2-amplified cells with IC50 of 149-944 nM. GDC-0941 inhibits proliferation of HER2-amplified cells that harbor PIK3CA mutations with IC50 of <500 nM, and effectively inhibits both proliferation and viability of HER2-amplified breast cancer cells that are resistant to trastuzumab due to PTEN loss. [2] GDC-0941 significantly inhibits the growth of HCT116, DLD1 and HT29 cells with GI50 of 1081 nM, 1070 nM and 157 nM, respectively. [3] GDC-0941 inhibits tumor cell proliferation, induces apoptosis and suppresses centroblast population. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
Sf9MVjLbY5ie2ViQYPzZZk>MoXaNUBpMWLEUXNQMmTHTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCSSUPLJJAyOTCmZXz0ZUBmgHC{ZYPz[YQhcW5iU3[5JINmdGy|IHPv[ZhxemW|c3nu[{BxQDWjbIDoZUB4cXSqIFnDOVAhd2ZiMD6wNFMh|ryPNIXKVowyQDd3NE[1OC=>
Sf9M3PI[mtqdmG|ZTDBd5NigQ>?NFPwb|UyKGh?MlHxSG1UVw>?NX7HR3VvUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDQTVNMKHBzMUDi[ZRiKEhzMES3MXIhdXW2YX70JIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNiY3;lfJBz\XO|aX7nJJA5PWGucHjhJJdqfGhiSVO1NEBw\iByLkCwN{DPxE1?NVLPNnc1OTh5NUS2OVQ>
Sf9NGL5WJlMcW6jc3WgRZN{[Xl?NVqzbGtOOSCqMUDEUXNQMoDHTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCSSUPLJJAyOTCkZYThJGU2PDVvSzDteZRidnRiZYjwdoV{e2WmIHnuJHNnQSClZXzsd{Bkd2W6cILld5NqdmdicEi1ZYxxcGFid3n0bEBKSzVyIH;mJFAvODB|IN88US=>NYPjZVVLOTh5NUS2OVQ>
Sf9M2PrNWtqdmG|ZTDBd5NigQ>?NWnrRlhVOSCqNHvVWZhFVVORM2rjV2lvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiUFmzT{BxOTFyYnX0ZUBmgHC{ZYPz[YQhcW5iU3[5JINmdGy|IHPv[ZhxemW|c3nu[{BxQDWjbIDoZUB4cXSqIFnDOVAhd2ZiMD6wN|Mh|ryPM4jaSVE5PzV2NkW0
Sf9NV3QUJc6U2mwYYPlJGF{e2G7MmLjNUBpMYjEUXNQM{[wNGlvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiUFmzT{BxOTFyYXzwbIEh\XiycnXzd4VlKGmwIGPmPUBk\WyuczDjc4V5eHKnc4PpcocheDh3YXzwbIE>NWDSeWdQOTh5NUS2OVQ>
MDA-MB-361M3GxVWZ2dmO2aX;uJGF{e2G7NGH2N2gzKGh?NV7GWlVLTE2VTx?=Mn21TY5pcWKrdHnvckBw\iCDa4SgV4VzPDd|IIDoc5NxcG:{eXzheIlwdiCrbjDoeY1idiCPRFGtUWIuOzZzIHPlcIx{KHerdHigVGlMO0ODIFW1OFUuUyCvdYTheIlwdiC5aYToJGlEPTBib3[gNE4xOjhizszNNWmyVGdvOTh5NUS2OVQ>
PC3MVzGeY5kfGmxbjDBd5NigQ>?NFLXcmMzKGh?NEfre4NFVVORNX3YVJd1UW6qaXLpeIlwdiCxZjDBb5QhW2W{NEezJJBpd3OyaH;yfYxifGmxbjDpckBRXEWQLX71cIwhcHWvYX6gVGM{KGOnbHzzJJdqfGhiSVO1NEBw\iByLkCzO{DPxE1?NV\VUI9LOTh5NUS2OVQ>
U87MGNIjrOYJHfW6ldHnvckBCe3OjeR?=MnvDNkBpM3PDUmROW09?MknZTY5pcWKrdHnvckBw\iCDa4SgV4VzPDd|IIDoc5NxcG:{eXzheIlwdiCrbjDQWGVPNW63bHygbJVu[W5iVUi3UWch[2WubIOge4l1cCCLQ{WwJI9nKDBwMES2JO69VQ>?M{H5VlE5PzV2NkW0
MDA-MB-361NYjm[XVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYjUNnZKQTZiaB?=MYXEUXNQNGfBT4pCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi1|NkGgZ4VtdHNid3n0bEBRUUt|Q1GgSVU1PS2NIH31eIF1cW:wIIfpeIghUUN3MDDv[kAxNjd{IN88US=>MnfPNVg4PTR4NUS=
A2780NGf2XmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFrWWHA6PiCqMlraSG1UVw>?M1vxcmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUK3PFAh[2WubIOge4l1cCCSSVuzR2Eh[W6mIGDUSW4hdXW2YYTpc44hf2m2aDDJR|UxKG:oIECuNVQh|ryPMUOxPFc2PDZ3NB?=
PC3M4DrbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml7ZPVYhcA>?MV7EUXNQM3Tqb2lEPTB;MD6yPEDPxE1?M{TQV|E5PzV2NkW0
U87MGMULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M17UTVk3KGh?NWj1dIR5TE2VTx?=MYXJR|UxRTBwOUWg{txONUe5PXNoOTh5NUS2OVQ>
Sf9MofZT4lv[XOnIFHzd4F6MkHwN|AhdWmwM3[1RmROW09?NF;2U2NKdmirYnn0bY9vKG:oIHj1cYFvKFCLM1vnZY1u[SCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgZY1wfW62IH;mJGFVWCClb37zeY1m\CC5aYToJGlEPTBib3[gNE4xPDJizszNM{Dk[FIzPTR6M{Sy
RAW 264.7NIPie|ZMcW6jc3WgRZN{[Xl?NVKzemNKQTBibXnuM4\PfmROW09?NGO2bY1KdmirYnn0bY9vKG:oIHj1cYFvKFCLM1vnZY1u[SCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCDS2SgdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjJ7ODFOwG0>MlzZNlI2PDh|NEK=
Sf9MmnzT4lv[XOnIFHzd4F6M{[xWFEhcA>?MU\Jcohq[mm2aX;uJI9nKEeVVD3meZNm\CCqdX3hckBz\WOxbXLpcoFvfCCSSUPLZoV1[SCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhW0Z7IHPlcIx{KHerdHigTWM2OCCxZjCwMlAyPyEQvF2=MkPBNlM2PDB4NEW=
Sf9NXuzOJlLU2mwYYPlJGF{e2G7MUOxJIg>NIHZZ49KdmirYnn0bY9vKG:oIFfTWE1nfXOnZDDoeY1idiC{ZXPvcYJqdmGwdDDQTVNM\GWudHGg[ZhxemW|c3XkMXmyN|U1ODZ2NR?=
Sf9Mm\nT4lv[XOnIFHzd4F6MUOxJIg>MknvTY5pcWKrdHnvckBw\iCJU2St[pV{\WRiaIXtZY4hemWlb33ibY5idnRiUFmzT4didW2jIHX4dJJme3OnZB?=MXKyN|U1ODZ2NR?=
Sf9NXXSWVZwU2mwYYPlJGF{e2G7MkXsNUBpNHvVV5BKdmirYnn0bY9vKG:oIFfTWE1nfXOnZDDoeY1idiC{ZXPvcYJqdmGwdDDQTVNM[WyyaHGg[ZhxemW|c3XkM13DNVI{PTRyNkS1
SKOV3NGr2UFlMcW6jc3WgRZN{[Xl?MWOxJO69VQ>?NUTvNlhnOSCqNWmzfI5iTE2VTx?=NFG4TItKdmirYnn0bY9vKG:oIGDJN2tidHCqYTDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFHreEBU\XJ2N{OgdIhwe3Cqb4L5cIF1cW:wM{DZOVI{OzZyM{S4
MCF7NVTiTo9PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnHNNUDPxE1?MXq5OkBpMWLEUXNQM324NmdKPTB;MD6wO|AzKM7:TR?=NWn1RnpwOjN|NkCzOFg>
SKOV3NGfWXoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX6xJO69VQ>?MXK5OkBpM{XROGROW09?NV7mdok4T0l3ME2wMlE1PzZizszNMYWyN|M3ODN2OB?=
PC3MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGLXS204OiCqM3zKfWROW09?M3PlXGlEPTB;MD6yPEDPxE1?Ml2yNlE6QDF5MUS=
MCF7.1M{G5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4DxdlczKGh?Mne3SG1UVw>?Mm\pRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPQ1[3MlEh[2WubIOg[ZhxemW|c3nu[{BJTVJ{IHflcoUhf2m2aDDJR|UxKG:oIECuNlgh|ryPMonlNlE6QDF5MUS=
MCF7-neo/Her2NEji[4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3zmdVczKGh?NYfvfYJUTE2VTx?=MX3JR|UxRTBwMkmg{txOMoqyNlM3PjJ7MEO=
MCF7-neo/Her2NHfGWINMcW6jc3WgRZN{[Xl?NUP6PWJiUW6qaXLpeIlwdiCxZjDQTVNM[WyyaHGgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIFHLWEBxcG:|cHjvdplt[XSrb36gZZQhWzR5MzD3bZRpKEmFNUCgc4YhOC5yMEeg{txONFn4TnQzOzZ4MkmwNy=>
PC3MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHrnS3Q4OiCqM3:xd2ROW09?NF7UOlNGSzVyPUCuN|Qh|ryPM3\pbFIyQTh3NkO5
MCF7.1MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYrlfXA2PzJiaB?=NFvQUnJFVVORNFPwOVBCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlcvOSClZXzsd{BmgHC{ZYPzbY5oKFCLM1vhcJBp[SCvdYThcpQhf2m2aDDFR|UxKG:oIECuN|kh|ryPMoDWNlE6QDV4M{m=
PC3M{facmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1P0flczKGh?NUjqS4FQTE2VTx?=NH7VeZJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDDN{Bk\WyuczDk[YZq[2mnboSgbY4hWFSHTjD3bZRpKEmFNUCgc4YhOC5|OTFOwG0>MkDPNlAxPTB4Nkm=
MCF7.1M2nO[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXHKTnBxPzJiaB?=MVPEUXNQNEXzc3BCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlcvOSClZXzsd{BmgHC{ZYPzbY5oKFCLM1vhcJBp[SCvdYThcpQhf2m2aDDJR|UxKG:oIECuN|Qh|ryPM4e5U|IxODVyNk[5
MCF7.1MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXLTUmpoPzJiaB?=M3uzZWVEPTB;MD63NkDPxE1?MVyyNFM1PjZ3Nh?=
NCI-H1975Ml\UR5l1d3SxeHnjJGF{e2G7NIHaclg4OiCqM36yd2lEPTB;MD6yO{DPxE1?MljnNlMxPTl3NEW=
H460M1nh[mN6fG:2b4jpZ{BCe3OjeR?=NXjvZY9kPzJiaB?=NWXIT245UUN3ME2wMlg4KM7:TR?=MlrDNlMxPTl3NEW=
HT-29MUHDfZRwfG:6aXOgRZN{[Xl?MXG3NkBpMYLJR|UxRTBwNk[g{txONWXub4R4OjNyNUm1OFU>
HepG2NHf4eopEgXSxdH;4bYMhSXO|YYm=NHPLdoc4OiCqMYfJR|UxRTFizszNMn;iNlMxPTl3NEW=
SGC7901NG\y[ldEgXSxdH;4bYMhSXO|YYm=NWnudplPPzJiaB?=M{\6U2lEPTB;MT64JO69VQ>?MYqyN|A2QTV2NR?=
NCI-H226M3m5NWN6fG:2b4jpZ{BCe3OjeR?=NWPFVnN1PzJiaB?=MVvJR|UxRTJwOTFOwG0>NYPXW4J1OjNyNUm1OFU>
A549NXHuPZpZS3m2b4TvfIlkKEG|c3H5MXi3NkBpNIXBXGpKSzVyPU[uPUDPxE1?MnOyNlMxPTl3NEW=
U87MGNViyTY1WS3m2b4TvfIlkKEG|c3H5M3j4ZlczKGh?NVzrWFBnUUN3ME23Mlc4KM7:TR?=MVyyN|A2QTV2NR?=
HBC4MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MY\sc4dIUTVyPT22MlA{KE1?NHu1e48zOjN|NkK0Oi=>
BSY1NV\zepd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmHScI9oT0l3ME2tOk46OCCPM2rPe|IzOzN4MkS2
HBC5MlLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4P5[Ixw\0eLNUC9MVYvPjBiTR?=M3TUPVIzOzN4MkS2
MCF7NXfud3VKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2m4Roxw\0eLNUC9MVcvOzNiTR?=NH:zem8zOjN|NkK0Oi=>
MDA-MB-231NYTyWJpST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUjFS2hMdG:pR1m1NF0uPS52NjDNNWPDeJhlOjJ|M{[yOFY>
U251MonCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mom2cI9oT0l3ME2tOU42OCCPNYj1W4gyOjJ|M{[yOFY>
SF268NFPRbFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3r1bYxw\0eLNUC9MVUvOzliTR?=NXnVOYNDOjJ|M{[yOFY>
SF295M{jJb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mli4cI9oT0l3ME2tOk4{PyCPNF\zPHgzOjN|NkK0Oi=>
SF539NXT4UnVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF3jR3Ftd2eJSUWwQU03NjVyIF2=MmCzNlI{OzZ{NE[=
SNB75MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIL0NVRtd2eJSUWwQU04NjFyIF2=NFjxVJAzOjN|NkK0Oi=>
SNB78NWLFPGpRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHrFdmZtd2eJSUWwQU03NjV{IF2=NHLZPXQzOjN|NkK0Oi=>
HCC2998NITaepJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXLsc4dIUTVyPT22MlI6KE1?NFzC[GszOjN|NkK0Oi=>
KM12MoGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mnr4cI9oT0l3ME2tOU44PiCPMl\xNlI{OzZ{NE[=
HT-29NXizSmNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYXsc4dIUTVyPT22MlMxKE1?M3rSPFIzOzN4MkS2
HCT15M3vib2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlnhcI9oT0l3ME2tOk4yOiCPNE\SeHIzOjN|NkK0Oi=>
HCT116MoDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWjxbJJQdG:pR1m1NF0uPS56NzDNMYWyNlM{PjJ2Nh?=
NCI-H23NULMU2tVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3\1OYxw\0eLNUC9MVUvPzNiTR?=NWH3cIlMOjJ|M{[yOFY>
NCI-H226MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUnJfGg2dG:pR1m1NF0uPi5{MTDNNEDvOI8zOjN|NkK0Oi=>
NCI-H522MnztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIjEbJNtd2eJSUWwQU03NjV6IF2=MVSyNlM{PjJ2Nh?=
NCI-H483MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1[xXYxw\0eLNUC9MVYvPTZiTR?=MnnnNlI{OzZ{NE[=
A549NXu0b2xRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYjweXdidG:pR1m1NF0uPi5zNTDNMnrENlI{OzZ{NE[=
DMS273NXTyXVJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGq4W49td2eJSUWwQU03NjR|IF2=NGHxcXYzOjN|NkK0Oi=>
DMS114NYDpWlFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX[yVZhUdG:pR1m1NF0uPS57MjDNM3XoclIzOzN4MkS2
LOXIMVIMkH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYS2NIZVdG:pR1m1NF0uPi5{OTDNMUeyNlM{PjJ2Nh?=
OVCAR3MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1TJOoxw\0eLNUC9MVYvPzFiTR?=M1LjWFIzOzN4MkS2
OVCAR4MnHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVLQNHBbdG:pR1m1NF0uPS55NjDNM4LQRVIzOzN4MkS2
OVCAR5MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2r1c4xw\0eLNUC9MVYvOjZiTR?=M1rDdFIzOzN4MkS2
OVCAR8NX3GNYJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NU\Jd3FMdG:pR1m1NF0uPS55MzDNNEizOIMzOjN|NkK0Oi=>
SKOV3NHHX[HZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHm2NZJtd2eJSUWwQU03NjV{IF2=MXOyNlM{PjJ2Nh?=
RXF631LMnnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVnsc4dIUTVyPT22Mlg5KE1?NVnnWY1VOjJ|M{[yOFY>
ACHNMWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYPYVYRPdG:pR1m1NF0uPi5yNzDNMUiyNlM{PjJ2Nh?=
St-4MlraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIL4Om5td2eJSUWwQU02NjV4IF2=NFnWXlYzOjN|NkK0Oi=>
MKN1M33KVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml;HcI9oT0l3ME2tO{4xQCCPNIHET48zOjN|NkK0Oi=>
MKN7NFzySWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFHkVIFtd2eJSUWwQU03NjVyIF2=NHXvOJczOjN|NkK0Oi=>
MKN28M3LLUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3noWoxw\0eLNUC9MVUvPTJiTR?=MXeyNlM{PjJ2Nh?=
MKN45MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXXvVpBKdG:pR1m1NF0uPi53NTDNNH;Qc3EzOjN|NkK0Oi=>
MKN74MoXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHXTRY5td2eJSUWwQU03NjB{IF2=M1zPRlIzOzN4MkS2
DU145NIX5RlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2jRcYxw\0eLNUC9MVUvQDViTR?=M1;rSVIzOzN4MkS2
PC3MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3XUPIxw\0eLNUC9MVYvPjZiTR?=M1\adlIzOzN4MkS2
ES5NHPBT5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGO2XZNKSzVyPUWwMlIyKG6PNYLBSWZGW0GQR1XS
HHMmjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlrsTWM2OD1zMUGuNFghdk1?NEL4NItUSU6JRWK=
MHH-PREB-1Mk\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2rLWmlEPTB;MUG0MlMhdk1?MXvTRW5ITVJ?
NCI-H1770M1u0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHXhNo5KSzVyPUGyN{45PiCwTR?=NXHpNVBXW0GQR1XS
HuO9MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mln5TWM2OD1{ME[uNFIhdk1?M37pbnNCVkeHUh?=
HAL-01M3TNfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NInMUIJKSzVyPUKwOk44OyCwTR?=NIfKXZZUSU6JRWK=
NOS-1M3Hud2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn;sTWM2OD1{MUGuPFIhdk1?NIn5[IJUSU6JRWK=
HGC-27M3jMfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUH4[m9UUUN3ME2yNVIvPTdibl2=MoC5V2FPT0WU
NB69MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NILqVZFKSzVyPUK0OU4zPyCwTR?=MkDGV2FPT0WU
RS4-11MmDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M13Q[2lEPTB;Mk[xMlc3KG6PNWj0T49lW0GQR1XS
DOKNXi2V2RLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX\JR|UxRTNyMT63JI5OM2TBdnNCVkeHUh?=
LB2241-RCCMVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2DXPGlEPTB;M{CzMlg1KG6PM3;hNnNCVkeHUh?=
NCI-H1623M4[yTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUHJR|UxRTNyND6wPEBvVQ>?MWjTRW5ITVJ?
YH-13NV33U4hFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUfJR|UxRTNyND6zNkBvVQ>?M2naWXNCVkeHUh?=
BPH-1NXzh[mxnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV7YdGlFUUN3ME2zNVQhdk1?NYrscpVbW0GQR1XS
AN3-CAM131emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVrJR|UxRTN2MD6zO{BvVQ>?MoS3V2FPT0WU
ES7Mo\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NInqSpBKSzVyPUO0NU46QSCwTR?=NFO2[3VUSU6JRWK=
MDA-MB-175-VIIMn\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFT5dHpKSzVyPUO1Nk46OiCwTR?=M4qyWHNCVkeHUh?=
GAMGNIW1cndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGrxVZNKSzVyPUO3NE45PSCwTR?=MoPmV2FPT0WU
CHL-1MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEOxcplKSzVyPUO3PE43PSCwTR?=NIfGV3dUSU6JRWK=
NB7Mn\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NILkeXNKSzVyPUO4PU45OyCwTR?=MXHTRW5ITVJ?
MFE-280Ml2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXHJR|UxRTRzOD6yJI5ONGrLVIFUSU6JRWK=
HL-60MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXjJR|UxRTR{NT63OUBvVQ>?MoTjV2FPT0WU
GCIYMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkOxTWM2OD12M{OuPEBvVQ>?MVTTRW5ITVJ?
MDA-MB-361M2jNZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2PaUmlEPTB;NEO5MlE{KG6PNUHpdZV2W0GQR1XS
LXF-289MlTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX\JXIxnUUN3ME20OFgvOjdibl2=NHjYfmVUSU6JRWK=
NBsusSRMUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXfJR|UxRTR6OD64OUBvVQ>?NXnXfWhSW0GQR1XS
KU-19-19M1rDZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYnCZ4J7UUN3ME21NVYvODdibl2=MoCwV2FPT0WU
A204M1\L[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2nJWmlEPTB;NUKyMlM{KG6PMXPTRW5ITVJ?
LB1047-RCCMkizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUH4SXBCUUN3ME21NlIvQTNibl2=MmTsV2FPT0WU
COLO-684NXfhSIlUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3jFWWlEPTB;NUKzMlEyKG6PMlL5V2FPT0WU
PA-1NHTiPZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYPtNG9zUUN3ME21N|IvPDFibl2=MkOxV2FPT0WU
MG-63M1i2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX31Z4FpUUN3ME21OFEvOTFibl2=M4Tw[XNCVkeHUh?=
BHT-101Mkf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVXpRlJuUUN3ME21OFQvQTRibl2=NXLSS|hHW0GQR1XS
NKM-1MkXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3\CdmlEPTB;NUmzMlA6KG6PMmL4V2FPT0WU
T47DNXvRcmt4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4nsNWlEPTB;NUm3MlU3KG6PNInrV5JUSU6JRWK=
MOLT-4M4PRPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIHOfGpKSzVyPU[yN{43OiCwTR?=NYHLW5ZTW0GQR1XS
IGROV-1Mlu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3fRZ2lEPTB;NkO0MlMyKG6PMX;TRW5ITVJ?
ES4MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX2welBKUUN3ME22N|kvPTRibl2=M3nBRnNCVkeHUh?=
HuO-3N1M2mzXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWPJR|UxRTZ2Mj6zPEBvVQ>?MUjTRW5ITVJ?
NEC8NH6yVWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUXPPYNkUUN3ME22OVMvPTdibl2=MXnTRW5ITVJ?
HO-1-N-1M4PkPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX;sTmR4UUN3ME22OVkvOTdibl2=MYPTRW5ITVJ?
EPCL-272HMmTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUXhb41TUUN3ME22PFcvOjFibl2=M1y2dnNCVkeHUh?=
D-263MGM{jYOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYnJcmFPUUN3ME23NVgvOSCwTR?=MVzTRW5ITVJ?
MV-4-11MkLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVjJR|UxRTd{ND6zNUBvVQ>?NYfPe25ZW0GQR1XS
SK-NEP-1MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYPv[VNOUUN3ME23NlUvQTRibl2=NVP3boVlW0GQR1XS
SW872M1PSTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYnJR|UxRTd{Nz64PUBvVQ>?MoDSV2FPT0WU
P30-OHKNGDXTG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MU\JR|UxRTd|MD63NUBvVQ>?MXTTRW5ITVJ?
OMC-1NUPp[|B7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlfvTWM2OD15NUGuNFkhdk1?MVPTRW5ITVJ?
LoVoNEHtbmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX7pbYYzUUN3ME23O|cvQSCwTR?=MnTTV2FPT0WU
LNCaP-Clone-FGCM{PC[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2n0S2lEPTB;N{m2MlM1KG6PNYHGdWRvW0GQR1XS
L-363Moe4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnHMTWM2OD15OUiuOFIhdk1?NIjSdGFUSU6JRWK=
ES8NFv1OpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2rFV2lEPTB;OEGwMlUzKG6PNF3WR|RUSU6JRWK=
697Mlv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWjJR|UxRTh|MT61OUBvVQ>?MU\TRW5ITVJ?
HSC-3MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2LRRmlEPTB;OEO5MlU1KG6PMVzTRW5ITVJ?
H4NHTRUmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXjQTpJXUUN3ME24OVAvQDVibl2=NUHWdm1MW0GQR1XS
QIMR-WILMlOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MU\JR|UxRTh4NT6yJI5OMYDTRW5ITVJ?
OAW-42M{fyV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUjrOY86UUN3ME24O|IvOTlibl2=MWTTRW5ITVJ?
MCF7NWfuXXpUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX;KZ4R6UUN3ME24PVgvPTlibl2=MYXTRW5ITVJ?
SCC-25MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUXJR|UxRTlzND6xPUBvVQ>?NIjud3dUSU6JRWK=
NCI-H1563M2qz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFnpN3pKSzVyPUmxOU46QSCwTR?=M2mxS3NCVkeHUh?=
OVCAR-5MlryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUDJR|UxRTl2MD6xO{BvVQ>?NH7FfYRUSU6JRWK=
HDLM-2Mm\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1fEUmlEPTB;OUS5MlIhdk1?MlHWV2FPT0WU
NB5NYDJc5ZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUfCZ3RbUUN3ME25OVYvPiCwTR?=NE\n[HRUSU6JRWK=
NCI-H292MoryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnroTWM2OD17N{SuN|Ihdk1?M3zMR3NCVkeHUh?=
A101DNIXmT4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1nyUWlEPTB;OUmwMlE6KG6PM3HpbnNCVkeHUh?=
NCI-H1648NFvEWpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGOyVoZKSzVyPUm5PE42OSCwTR?=NI\tTHhUSU6JRWK=
EKVXM3fn[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlLVTWM2OD1zLkCxNlkh|ryPMkDJV2FPT0WU
SW1710NFnOZ5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX3XeVlGUUN3ME2xMlA1OjN|IN88US=>MV3TRW5ITVJ?
WM-115NFHwXnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1vqPGlEPTB;MT6wOlY2PiEQvF2=NULmVWtEW0GQR1XS
CAL-54M2\SS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MY\JR|UxRTFwMEewPFEh|ryPNUnuO2M{W0GQR1XS
TGBC24TKBMX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkTCTWM2OD1zLkC4NFQ2KM7:TR?=NV3OWFdOW0GQR1XS
NCI-H520NIDQ[oJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml\JTWM2OD1zLkC4PVY4KM7:TR?=MljxV2FPT0WU
D-423MGMmK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVvJR|UxRTFwMEm5OlIh|ryPNUPlXJpUW0GQR1XS
BFTC-905NHrGUnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWWzd5FWUUN3ME2xMlE{PDR7IN88US=>MVPTRW5ITVJ?
HTMkLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUTJR|UxRTFwMUO0O|gh|ryPNUDPcHNuW0GQR1XS
CTB-1MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXSwWnU3UUN3ME2xMlE1Ojl|IN88US=>NXjnb2tSW0GQR1XS
Hs-578-TM{nJZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGjQTFZKSzVyPUGuNVk2PjVizszNNVrJO2pjW0GQR1XS
HuH-7NYHoRYFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4LGTGlEPTB;MT6yNFk1QSEQvF2=NX3oOGxbW0GQR1XS
LB996-RCCNFLQUpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3noeGlEPTB;MT6yNlE4PyEQvF2=NHmzWGhUSU6JRWK=
KYSE-270M2DvUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUnYXnF1UUN3ME2xMlI6PzN2IN88US=>M3zId3NCVkeHUh?=
A4-FukMnnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVXJR|UxRTFwMkm5PVMh|ryPMkDpV2FPT0WU
A498NXLjdGJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX\JR|UxRTFwM{C0O|Qh|ryPNH\TRYpUSU6JRWK=
SK-MEL-1NF7XeZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUDDbFM4UUN3ME2xMlMxPjd7IN88US=>M{\POXNCVkeHUh?=
AU565M1zXRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUfJR|UxRTFwM{G4OlMh|ryPMVvTRW5ITVJ?
Saos-2NYfs[pFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYe2eWhDUUN3ME2xMlM{OjB3IN88US=>NVHJZWVxW0GQR1XS
A549NVe3TFAxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NInUTmdKSzVyPUGuN|k6PyEQvF2=MYrTRW5ITVJ?
BFTC-909M2n2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NI\SNYJKSzVyPUGuOFM{ODVizszNM4PaOHNCVkeHUh?=
MDA-MB-415MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnrmTWM2OD1zLkS4OlkzKM7:TR?=NYLFNXk3W0GQR1XS
639-VNUnR[VM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2jxXWlEPTB;MT61NFI1PSEQvF2=MkH2V2FPT0WU
A704M{C3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2LlUGlEPTB;MT61NFc5PSEQvF2=NFjuPHFUSU6JRWK=
PANC-03-27MoPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUT4PWJRUUN3ME2xMlUyPDB6IN88US=>NIPjeXpUSU6JRWK=
SK-MEL-28MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX;JR|UxRTFwNU[wPFUh|ryPMkTUV2FPT0WU
Ramos-2G6-4C10NX[yfGtRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEW4UnpKSzVyPUGuOlA4PDZizszNNHjCXIFUSU6JRWK=
HuP-T4NFH4Z3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX;JR|UxRTFwNkC3O|gh|ryPNGLwXWlUSU6JRWK=
VA-ES-BJMoW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXPJR|UxRTFwNkGyO{DPxE1?MWXTRW5ITVJ?
EFM-19MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWXJR|UxRTFwNkG4NUDPxE1?NWXzNpV3W0GQR1XS
G-401NHnoXmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlewTWM2OD1zLk[yNVY1KM7:TR?=M{nvTnNCVkeHUh?=
D-566MGM{XabWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXnEUIVZUUN3ME2xMlYzPTNizszNMXjTRW5ITVJ?
JVM-3M{jnZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M37LTWlEPTB;MT62OFg4PSEQvF2=MVvTRW5ITVJ?
TK10NXnxTpJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF3TcnJKSzVyPUGuOlcxQDNizszNNEPBU5hUSU6JRWK=
BT-20M3fUS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYDQXJI3UUN3ME2xMlY5QTB{IN88US=>M2rDWHNCVkeHUh?=
EGI-1MoXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXPZRWI{UUN3ME2xMlg1PzBzIN88US=>Mmi2V2FPT0WU
EW-16NF\jb2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXzJR|UxRTFwOEWxPFIh|ryPMlnnV2FPT0WU
NCI-H2228NUSyU4RoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXXJR|UxRTFwOEWyNFMh|ryPNUjkeWNGW0GQR1XS
BB49-HNCMn;nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1;me2lEPTB;MT64PFY6OiEQvF2=MXfTRW5ITVJ?
G-402Ml:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWfUPFVVUUN3ME2xMlg6Pzl5IN88US=>MnX5V2FPT0WU
NCI-H526NYDiO5BzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnrBTWM2OD1zLkmxN|kh|ryPNELGdJVUSU6JRWK=
ME-180MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MY\JR|UxRTFwOUO0O|ch|ryPMX\TRW5ITVJ?
PFSK-1MkHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1fFe2lEPTB;MT65OFQ2QCEQvF2=MUjTRW5ITVJ?
TYK-nuNX;3[m0{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXf4Z4t5UUN3ME2xMlk2QDJ|IN88US=>MVHTRW5ITVJ?
HOSMoHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX7JR|UxRTFwOUe5OFgh|ryPM4HoV3NCVkeHUh?=
T98GMmC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWG0SpVwUUN3ME2xMlk6ODB4IN88US=>M4jkUHNCVkeHUh?=
SK-MES-1NFv5NGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3HVPWlEPTB;Mj6wNVM{OiEQvF2=NVe2UJc2W0GQR1XS
SNB75NX;Ub|V2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1\NRmlEPTB;Mj6wNVU1OSEQvF2=Mkj3V2FPT0WU
LAMA-84MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFroUItKSzVyPUKuNFI3QDlizszNNWrZcIZ7W0GQR1XS
CAL-39M2HIcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV7JR|UxRTJwMEOyPEDPxE1?NUiy[lBtW0GQR1XS
LOXIMVIM{Oz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoC1TWM2OD1{LkC0NFg1KM7:TR?=NXnYSlhPW0GQR1XS
NH-12NFXQcHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWq3WIFxUUN3ME2yMlA2PDJ2IN88US=>M2nlRnNCVkeHUh?=
NCI-H1048M{S3XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2TTfWlEPTB;Mj6xNFUzKM7:TR?=M1vKfHNCVkeHUh?=
KS-1NYHu[VdMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3zSTWlEPTB;Mj6xNVAxOSEQvF2=NUnWdYNnW0GQR1XS
NCI-N87Mn:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4G4VWlEPTB;Mj6xN|M5PCEQvF2=NFH1Rm1USU6JRWK=
CHP-212M1jRUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFfycotKSzVyPUKuNVg1PDJizszNMn;2V2FPT0WU
HCC1419NV3sVlJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXnpW3FGUUN3ME2yMlIyOTF3IN88US=>NWfucpoyW0GQR1XS
ES1NWfLdItHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NImybHhKSzVyPUKuNlE{OjZizszNNHfjfpdUSU6JRWK=
NCI-H2030MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoTBTWM2OD1{LkK0NVI{KM7:TR?=NX3I[ml{W0GQR1XS
EW-22NUXFRWVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3\zdGlEPTB;Mj6yOVA3PyEQvF2=MUjTRW5ITVJ?
A431NXLRdWs4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGHxTpdKSzVyPUKuNlc{PTRizszNMVvTRW5ITVJ?
SF126NETnfllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH31dmVKSzVyPUKuN|A3OjVizszNNUW2SVJ[W0GQR1XS
SF295M2HFfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYrweGhPUUN3ME2yMlMyPTJ2IN88US=>MmTiV2FPT0WU
D-502MGM4LBcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWPpXHhmUUN3ME2yMlMzPDZzIN88US=>M4faXXNCVkeHUh?=
HCC2157MlPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYjJR|UxRTJwM{K5Nlch|ryPMX;TRW5ITVJ?
D-283MEDNVzFXm8{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFnlNJlKSzVyPUKuN|U6OjZizszNNWnBSINbW0GQR1XS
SNU-423NGnwWZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV3JR|UxRTJwNECxO|Eh|ryPNWrpdmpRW0GQR1XS
SK-LU-1NWOwRmg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlTSTWM2OD1{LkS0OVg3KM7:TR?=M1u0d3NCVkeHUh?=
22RV1MljrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYf2Olh{UUN3ME2yMlQ2PjF5IN88US=>NXTQXWpVW0GQR1XS
SW1088Mk\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGDrWYFKSzVyPUKuOFkzOTNizszNMXjTRW5ITVJ?
HT-3NEfuNXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGjB[|FKSzVyPUKuOFkzPTlizszNMXrTRW5ITVJ?
NCI-H1666MoLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M33MbmlEPTB;Mj61NVExPCEQvF2=MonJV2FPT0WU
EM-2M2LBbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3rmR2lEPTB;Mj61NVE3QSEQvF2=NW\QVGNHW0GQR1XS
SNU-449NYjJ[Vl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mo\GTWM2OD1{LkW3NFE1KM7:TR?=NYfrRWpTW0GQR1XS
786-0Mn\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MojSTWM2OD1{LkW5NlM5KM7:TR?=MnfMV2FPT0WU
SKG-IIIaMorHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3LXbWlEPTB;Mj62OVk{QSEQvF2=NH32dlhUSU6JRWK=
MEL-HONIfJdXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH25c2ZKSzVyPUKuOlc3OzRizszNMorHV2FPT0WU
LCLC-97TM1NXnsR2lXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mly1TWM2OD1{Lk[5NlY4KM7:TR?=M3XCfXNCVkeHUh?=
MKN7NIDDS4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVrkcGFLUUN3ME2yMlcxPzV2IN88US=>NF3reJpUSU6JRWK=
5637NVPnN4V{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHvEUGxKSzVyPUKuO|ExOzVizszNMl7vV2FPT0WU
HOP-92M3np[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmfjTWM2OD1{Lke0O|E4KM7:TR?=MWfTRW5ITVJ?
MDA-MB-157Mn7TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{XpNGlEPTB;Mj64NlAzOyEQvF2=M3HvVHNCVkeHUh?=
NB12NUXyZolPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3rucGlEPTB;Mj64OFkyPCEQvF2=M3TUcnNCVkeHUh?=
DMS-273MkfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYTJR|UxRTJwOE[0O{DPxE1?M{C4NXNCVkeHUh?=
HCC70M2XlUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV;mWJhqUUN3ME2yMlg3PTh7IN88US=>MX\TRW5ITVJ?
YKG-1M33hU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWHJR|UxRTNwMEO3PFch|ryPMYnTRW5ITVJ?
NCI-H28NFKxfIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4TTTWlEPTB;Mz6wOVI6OSEQvF2=NWL0elJYW0GQR1XS
HNMX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYTJR|UxRTNwME[2N|Yh|ryPMXvTRW5ITVJ?
HT-1080M1vpVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlvrTWM2OD1|LkC4OlA3KM7:TR?=NVrMNJRSW0GQR1XS
HPAF-IINUCwS21RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2[3SGlEPTB;Mz6xNFA3QCEQvF2=M12yTXNCVkeHUh?=
U-2-OSNUTNdZVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYC2fFZtUUN3ME2zMlE{Pzh{IN88US=>NYruNFRDW0GQR1XS
SNU-387M2nvc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3jaXGlEPTB;Mz6xOlM3PCEQvF2=MnG1V2FPT0WU
BeckerNFjrWINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHzDTodKSzVyPUOuNVY5ODhizszNNFvh[JhUSU6JRWK=
BHYMUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVPJR|UxRTNwMkW1O|Eh|ryPMWrTRW5ITVJ?
HTC-C3M3n4[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVXNPGFmUUN3ME2zMlI6OzV{IN88US=>M{P6N3NCVkeHUh?=
M14MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX3NSpdXUUN3ME2zMlMxPjZ|IN88US=>NFmxXpZUSU6JRWK=
COR-L23Mn\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFvvdmhKSzVyPUOuN|czPzlizszNNIfJSGRUSU6JRWK=
C32MmTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGnDSZJKSzVyPUOuOFE2ODhizszNNX\iOJVkW0GQR1XS
MewoNHTMWWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFjuRmpKSzVyPUOuOFIyQDJizszNMnLzV2FPT0WU
TE-8M{jxOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVKxN3JvUUN3ME2zMlQ5OjV7IN88US=>NFfLR|BUSU6JRWK=
RPMI-2650MmGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWDJR|UxRTNwNkC2N|ch|ryPMoDmV2FPT0WU
AGSMn7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIq5cppKSzVyPUOuOlI1PjRizszNNFO5XmZUSU6JRWK=
MZ2-MELMYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVHnb|UxUUN3ME2zMlY3OTN6IN88US=>NHrXPIlUSU6JRWK=
Calu-3NWnadVJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX7JR|UxRTNwN{GyPFch|ryPNXTkUotzW0GQR1XS
SJSA-1NVfMUnhFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoTNTWM2OD1|LkexN|E2KM7:TR?=NXO1coJQW0GQR1XS
SW962NXX5fYhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlHMTWM2OD1|LkeyOlM3KM7:TR?=NXfRZolxW0GQR1XS
PC-14MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXHJR|UxRTNwN{OyNlIh|ryPNV7JOo05W0GQR1XS
SW1573MkjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX\abWtSUUN3ME2zMlc2OzR6IN88US=>MXPTRW5ITVJ?
769-PM{LaNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4H4eWlEPTB;Mz64Nlc1OyEQvF2=NFvibGNUSU6JRWK=
KNS-62NWLB[XFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn\vTWM2OD1|LkmyN|M5KM7:TR?=Mlm2V2FPT0WU
NCI-H747MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmnzTWM2OD12LkC1OlM5KM7:TR?=Mn30V2FPT0WU
LN-405MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml\hTWM2OD12LkG1O|I5KM7:TR?=NVjjeVR6W0GQR1XS
OVCAR-8MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MojETWM2OD12LkKyOVQ{KM7:TR?=NUnNOINGW0GQR1XS
DMS-114MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUTJR|UxRTRwMkO4PVEh|ryPMknxV2FPT0WU
NCI-H2126M3;vVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1S3TGlEPTB;ND6yOFU2QCEQvF2=M1zXXHNCVkeHUh?=
TCCSUPMmTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIrBO41KSzVyPUSuNlQ4QDhizszNM2\zeXNCVkeHUh?=
SK-N-FIMmPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYHZdZpUUUN3ME20MlI2OzN{IN88US=>MkC0V2FPT0WU
HCE-4MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3;XPWlEPTB;ND6yO|E6PyEQvF2=MXvTRW5ITVJ?
DK-MGNEHkdotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEP2W5RKSzVyPUSuN|A{QSEQvF2=MYjTRW5ITVJ?
RO82-W-1MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF\iW|dKSzVyPUSuN|I2QDRizszNM4nIZ3NCVkeHUh?=
A2780MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlTwTWM2OD12LkO2OlgzKM7:TR?=M2fLeXNCVkeHUh?=
ETK-1Mmm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1:0VmlEPTB;ND6zO|A2OiEQvF2=Ml7xV2FPT0WU
FADUNWH5VJlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlPjTWM2OD12LkO3OFY4KM7:TR?=NE\WNppUSU6JRWK=
CAL-12TMWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmD6TWM2OD12LkSxOFE{KM7:TR?=M{S4c3NCVkeHUh?=
647-VMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M37ZS2lEPTB;ND60OFAzOiEQvF2=MkXZV2FPT0WU
TGBC1TKBMl3XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYDJR|UxRTRwNEWxNVMh|ryPMn\FV2FPT0WU
LU-99AMlTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NID1VmVKSzVyPUSuOFYxPiEQvF2=NVPPTVBTW0GQR1XS
CAL-33NGDnflJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1fYbWlEPTB;ND61NlQ2PiEQvF2=NGTZbmlUSU6JRWK=
LU-134-AMmXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWLJR|UxRTRwNUK3OFUh|ryPMYjTRW5ITVJ?
NCI-H1355NGPh[FBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXviWoYyUUN3ME20MlU2OTR4IN88US=>MlzCV2FPT0WU
RPMI-7951MmPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF;CcZdKSzVyPUSuOVcxODJizszNNYD5O3BnW0GQR1XS
TE-1MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnzJTWM2OD12Lk[2NVQ{KM7:TR?=MX7TRW5ITVJ?
OE33MoTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnLRTWM2OD12LkewOVEyKM7:TR?=NX64NWk3W0GQR1XS
CAL-51M1GyTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHjXco5KSzVyPUSuO|ExQDJizszNM{HodXNCVkeHUh?=
SW1783NY\FeHpXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoHkTWM2OD12Lke1N|A5KM7:TR?=NFfiblVUSU6JRWK=
BT-474MmmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIjpdY1KSzVyPUSuO|Y{QDRizszNMnLrV2FPT0WU
KYSE-520M{DFUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIm0cVRKSzVyPUSuPFc{QTJizszNMmTkV2FPT0WU
8-MG-BAMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUXJR|UxRTRwOEi1OVch|ryPNX:2ToV7W0GQR1XS
IA-LMMkjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml\WTWM2OD12Lkm5OFM2KM7:TR?=M1T4XHNCVkeHUh?=
SW954M13BSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{PkT2lEPTB;ND65PVQ1OyEQvF2=MW\TRW5ITVJ?
RPMI-8226NF3NO|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXjPOpM2UUN3ME21MlA2PDZzIN88US=>MVTTRW5ITVJ?
MKN1MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXnHOo81UUN3ME21MlA4QTJ5IN88US=>NY\JbXBxW0GQR1XS
A375M1uxR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX:1NHlvUUN3ME21MlA6OjV4IN88US=>MlGxV2FPT0WU
8305CMYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFjJcZFKSzVyPUWuNFk5QDdizszNMlO0V2FPT0WU
CAL-62M3\ZVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIDDSmpKSzVyPUWuNVgzPTlizszNNVHFR5lFW0GQR1XS
NB10M4f4UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmO2TWM2OD13LkKyO|Q1KM7:TR?=MVrTRW5ITVJ?
OC-314Mmr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXX4R5A{UUN3ME21MlM4PDR2IN88US=>NUf4NHlnW0GQR1XS
PSN1NVn3WmpNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{HDRmlEPTB;NT6zPFI5PiEQvF2=NE\ZR3dUSU6JRWK=
GR-STMmXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1vkfGlEPTB;NT6zPFMzOiEQvF2=MoLsV2FPT0WU
P12-ICHIKAWANEXoVFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVz6TXdZUUN3ME21MlQxOSEQvF2=MlXHV2FPT0WU
NCI-H1092MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHHYXVNKSzVyPUWuOFEyPDhizszNMn64V2FPT0WU
SCC-4NVvSO4d{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHH5Tm1KSzVyPUWuOFE{PTVizszNNGnSR3pUSU6JRWK=
TE-6MlPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mof4TWM2OD13LkSxPFE3KM7:TR?=M2ryU3NCVkeHUh?=
DOHH-2NYm3RYRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV3JRXhTUUN3ME21MlQzOjR6IN88US=>NUHLWJpsW0GQR1XS
SW684MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVfJR|UxRTVwNk[zPFUh|ryPM1nobHNCVkeHUh?=
CP50-MEL-BM2jyTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn3VTWM2OD13Lk[4Olg1KM7:TR?=MmLZV2FPT0WU
UM-UC-3NGPsc4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF3LV5BKSzVyPUWuO|IzOzFizszNM1jWN3NCVkeHUh?=
LC-2-adM3jMXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWPXS25lUUN3ME21Mlc5OjVzIN88US=>MYHTRW5ITVJ?
PC-3Mnq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYjaTZN3UUN3ME21MlkyPjF3IN88US=>M{L5ZnNCVkeHUh?=
CANNXW5[Y5{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoTKTWM2OD13LkmyPFIh|ryPNF22W45USU6JRWK=
ESS-1M3nmVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2nvPWlEPTB;NT65O|g3QSEQvF2=Mk\vV2FPT0WU
ATN-1NHXreYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2Lo[GlEPTB;Nj6wOVU3QCEQvF2=MkLzV2FPT0WU
BxPC-3MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEfF[nhKSzVyPU[uNFgzOTlizszNNGXrVY5USU6JRWK=
KYSE-150MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXPJR|UxRTZwMUK0O|Yh|ryPNIH4c5lUSU6JRWK=
RPMI-8866NW\ueHRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MojxTWM2OD14LkG5NVY{KM7:TR?=M4q5eXNCVkeHUh?=
SW780MmPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWjJR|UxRTZwMkC0NkDPxE1?NFO1RXdUSU6JRWK=
A388MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEHuV2FKSzVyPU[uNlMyOTVizszNMl33V2FPT0WU
NCI-H1437M{CzWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVPJR|UxRTZwMkSwO|Mh|ryPM1z6VHNCVkeHUh?=
NCI-H1755NGDocGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHPKOG5KSzVyPU[uN|Y3OTJizszNM4jJTHNCVkeHUh?=
LS-123MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFvVVmZKSzVyPU[uOFA2OjFizszNM1LFSnNCVkeHUh?=
CaR-1MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHHGVnhKSzVyPU[uOFY{PzNizszNMWXTRW5ITVJ?
RT-112NHPaNVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3XFeGlEPTB;Nj62NFM{QCEQvF2=MVPTRW5ITVJ?
CGTMWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml;BTWM2OD14LkezOlgyKM7:TR?=NWHjSGdHW0GQR1XS
SW626MoLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHvIcplKSzVyPU[uO|M6PDZizszNMnrFV2FPT0WU
AsPC-1M4fDWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX;JR|UxRTZwN{S1NFch|ryPNXfkRlRPW0GQR1XS
SBC-5NGPrVJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mne3TWM2OD14Lkm3Nlk4KM7:TR?=MoXvV2FPT0WU
SF539NYDibHZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV3JR|UxRTZwOUmzN|Mh|ryPM3LFN3NCVkeHUh?=
TI-73MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1rVfWlEPTB;Nz6wOlI5PSEQvF2=NWe0UohNW0GQR1XS
MHH-ES-1NVfGfoxGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4PCO2lEPTB;Nz6wO|c3OiEQvF2=MlfsV2FPT0WU
KYSE-510MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHX5UplKSzVyPUeuNFg1OzJizszNM4K3VnNCVkeHUh?=
EW-1MnGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWrkdI44UUN3ME23MlM3QTl4IN88US=>NXfxWXFHW0GQR1XS
SK-OV-3MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUjJR|UxRTdwM{m0N|Ih|ryPMYXTRW5ITVJ?
MC-IXCMnrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlruTWM2OD15LkSxPVczKM7:TR?=Ml7jV2FPT0WU
HSC-2NWDVWotyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVjJR|UxRTdwNEK3NFUh|ryPMlTLV2FPT0WU
NCI-H2342M{OwN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF7aNJlKSzVyPUeuOVE1QSEQvF2=NWm0b2hxW0GQR1XS
NCI-H1792NHjwV41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHW3TnRKSzVyPUeuOVE4OTFizszNNUPXdXY5W0GQR1XS
HT-1376Mn3nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M33hWGlEPTB;Nz64O|c4QCEQvF2=NVXFR3hMW0GQR1XS
EW-13M33pc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MorhTWM2OD15Lki5PVc4KM7:TR?=Mki1V2FPT0WU
no-11M2C2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVTJR|UxRTdwOUCxO|Qh|ryPNX;ac2p5W0GQR1XS
DaoyNFL6Z3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVTJR|UxRTdwOUSzNlEh|ryPMmfwV2FPT0WU
COLO-800NH7KSppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUHJR|UxRThwMESxOlIh|ryPMnrpV2FPT0WU
GB-1M3HzNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUHJR|UxRThwME[1OlUh|ryPM1fZVnNCVkeHUh?=
SJRH30MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIfIbG5KSzVyPUiuNVU5PzhizszNNXj5dWFkW0GQR1XS
NCI-H2291MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2HNdmlEPTB;OD6yPVE5PyEQvF2=MWjTRW5ITVJ?
J82NGLVe5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml3rTWM2OD16LkK5OFkyKM7:TR?=M{XJbXNCVkeHUh?=
NCI-H596MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUHjV3pRUUN3ME24MlMyPDV|IN88US=>MU\TRW5ITVJ?
RERF-LC-MSNVTDbJBkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYrNdJBMUUN3ME24MlM1QDV4IN88US=>NXm5bpFuW0GQR1XS
RH-18M172W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGK4cGtKSzVyPUiuN|UxPDZizszNMXjTRW5ITVJ?
SW48M2PSOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH33c|dKSzVyPUiuOVk1PTNizszNMX;TRW5ITVJ?
RDM1HZeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRThwNUmzPVEh|ryPM1\mWHNCVkeHUh?=
MS-1NU[zfY97T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUjJR|UxRThwNkGzPFch|ryPNHjQXFRUSU6JRWK=
ES6NVq0ZmY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXX4UGZHUUN3ME24Mlc{OTF7IN88US=>M17vbXNCVkeHUh?=
TE-12NEjwfG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3XIZ2lEPTB;OD63O|UxPSEQvF2=NInMZm1USU6JRWK=
DBTRG-05MGNEPrTVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2H2ZWlEPTB;OD65NVIyPyEQvF2=NFz2b|dUSU6JRWK=
KINGS-1NVfZZY1KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIDk[WJKSzVyPUiuPVI6OzhizszNM3P6OnNCVkeHUh?=
HLEMnzES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYDJR|UxRThwOUO3PFUh|ryPNEPXVJBUSU6JRWK=
MHH-NB-11MnrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUTJR|UxRTlwMEG4N|kh|ryPMoXRV2FPT0WU
U-87-MGM4\kOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXPJR|UxRTlwMkSzNlEh|ryPNWnhNJVVW0GQR1XS
MN-60MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGTE[ZpKSzVyPUmuNlQ2PDJizszNMV3TRW5ITVJ?
SASM17MRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEDyUItKSzVyPUmuNlU2QDFizszNNYnCTpdHW0GQR1XS
NCI-H446MkHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYS4[FNrUUN3ME25MlM3OSEQvF2=Ml3sV2FPT0WU
C-33-AM1jFXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoPtTWM2OD17LkSzPVg5KM7:TR?=NYi0fI56W0GQR1XS
RXF393NHjn[2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFHqRYNKSzVyPUmuOFcxODJizszNNV\aPWdtW0GQR1XS
CGTH-W-1NGLjVGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHHQWldKSzVyPUmuOFk{QDRizszNMYXTRW5ITVJ?
RCM-1MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mny3TWM2OD17Lk[zPFAyKM7:TR?=Ml71V2FPT0WU
SN12CMVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHPQO3pKSzVyPUmuOlU{OzhizszNM3L1VHNCVkeHUh?=
KLEMWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3[xfWlEPTB;OT63NFAxQSEQvF2=NEX5WWNUSU6JRWK=
EFO-21M4\acGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWnJR|UxRTlwN{ezPFIh|ryPMWLTRW5ITVJ?
KYSE-70NH;3NphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1rTbWlEPTB;OT64PFAyOSEQvF2=NULUdXhoW0GQR1XS
D-247MGMYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3vmfWlEPTB;MUCuNFU3QCEQvF2=MonsV2FPT0WU
MPP-89NGTTfHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEniO5pKSzVyPUGwMlA6PDZizszNNIjjU4tUSU6JRWK=
RVH-421NH7ZXGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWjJR|UxRTFyLkG1NFUh|ryPM3fYPHNCVkeHUh?=
NCI-H460NX[wbmR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NULPToFEUUN3ME2xNE4zQDB4IN88US=>NYL0WmRFW0GQR1XS
NOMO-1NV7KbmFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVzQbYN{UUN3ME2xNE4{PTN{IN88US=>M1zmRnNCVkeHUh?=
DELMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYniXYd{UUN3ME2xNE4{Pzl2IN88US=>NVzwWHFWW0GQR1XS
HT55M{fMfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NITFeWpKSzVyPUGwMlYzODVizszNMWTTRW5ITVJ?
MC116NX7wPVdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnvDTWM2OD1zMD62OlU2KM7:TR?=MUnTRW5ITVJ?
BB30-HNCMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIDzfVJKSzVyPUGwMlY3QSEQvF2=NFjYbnJUSU6JRWK=
DJM-1MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnjYTWM2OD1zMD62PVQ6KM7:TR?=MYPTRW5ITVJ?
ZR-75-30MlPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYHjTJpsUUN3ME2xNE46PDRzIN88US=>MnS5V2FPT0WU
U-118-MGM{DpPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4\FNmlEPTB;MUCuPVg6PiEQvF2=M2q0dnNCVkeHUh?=
MSTO-211HMnzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGLrc2ZKSzVyPUGxMlA4OTZizszNM3WybXNCVkeHUh?=
SW837NYLEcI1RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M173SWlEPTB;MUGuNFk1QSEQvF2=NYnoW2FjW0GQR1XS
HuCCT1MkjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGLXUlNKSzVyPUGxMlEzQDFizszNNFfZXm1USU6JRWK=
RCC10RGBMYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV7JR|UxRTFzLkGzOUDPxE1?M2nMS3NCVkeHUh?=
NMC-G1MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUPJR|UxRTFzLkG0PVMh|ryPMnzUV2FPT0WU
NCI-H650M2j0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXu5OYRWUUN3ME2xNU4{Pzl2IN88US=>M3Hs[3NCVkeHUh?=
HEC-1NVj6N|h[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3nJRmlEPTB;MUGuOFMzQCEQvF2=NHrqenNUSU6JRWK=
DU-4475MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2K0cGlEPTB;MUGuO|M6OyEQvF2=MmfYV2FPT0WU
DSH1MlHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{WwNmlEPTB;MUGuO|YxPiEQvF2=Mo\0V2FPT0WU
HCC1569M3LKXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFjmfGlKSzVyPUGxMlc3PzhizszNMVXTRW5ITVJ?
HCC1187NV3VZZlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1TadGlEPTB;MUGuPFU5QCEQvF2=NWPiSVk4W0GQR1XS
EW-11Mn\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4jYWWlEPTB;MUGuPVQ4PCEQvF2=MnzZV2FPT0WU
LB2518-MELNHzxVFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIDRSIJKSzVyPUGyMlA2QSEQvF2=M4XES3NCVkeHUh?=
KALS-1MoTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVjQVpJRUUN3ME2xNk45PTV|IN88US=>MlLnV2FPT0WU
8505CNXrWcGF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX\lWZdvUUN3ME2xNk45QDVizszNNYfW[|lkW0GQR1XS
SK-N-DZMXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVPJR|UxRTF|LkC0OVMh|ryPM{HZbHNCVkeHUh?=
CHP-134Ml60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHm2UYxKSzVyPUGzMlEyPThizszNMkTYV2FPT0WU
HCE-TNWH3[WlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWHJR|UxRTF|LkKzOlQh|ryPM1\VU3NCVkeHUh?=
LB-831-BLCM3XNNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVrJR|UxRTF|Lk[yOFYh|ryPNFrqTZFUSU6JRWK=
OVCAR-4M3LmfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlPvTWM2OD1zMz62OVI1KM7:TR?=NVT6T|JNW0GQR1XS
SW756MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlG4TWM2OD1zMz63NlQ3KM7:TR?=MWHTRW5ITVJ?
OCUB-MNIXhW5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXLJR|UxRTF|LkixOVYh|ryPMkX1V2FPT0WU
SW982M3XVb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkDaTWM2OD1zMz64Nlc3KM7:TR?=NGDGTZVUSU6JRWK=
DBM1LpXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYHaOZFDUUN3ME2xN{45Ozh2IN88US=>MYLTRW5ITVJ?
H-EMC-SSNGTpW3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnHzTWM2OD1zMz65NVM6KM7:TR?=MYPTRW5ITVJ?
VMRC-RCZM4Pqfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGnD[4dKSzVyPUG0MlAxOTVizszNMXrTRW5ITVJ?
CAKI-1MkfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWnJR|UxRTF2LkCxN|Ih|ryPM2\ac3NCVkeHUh?=
GI-1NYrFSY1DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mo\ZTWM2OD1zND6wOlU5KM7:TR?=Mn24V2FPT0WU
Ca9-22NInwTXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXXGc4RCUUN3ME2xOE43ODV2IN88US=>NYfOOVVYW0GQR1XS
TE-5NU\VXFRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnyxTWM2OD1zND63NlA5KM7:TR?=M1XIe3NCVkeHUh?=
EFO-27MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEG4ZmZKSzVyPUG0Mlc3OjJizszNNWnjTIV1W0GQR1XS
CAL-72M1zRWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUXJR|UxRTF2Lke3PFMh|ryPNEe3clNUSU6JRWK=
GP5dM1Ltbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnroTWM2OD1zNT6wOFc1KM7:TR?=MnHVV2FPT0WU
CAS-1NX\QfI1sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoXDTWM2OD1zNT6wOlYh|ryPMXzTRW5ITVJ?
A2058MnH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFHTTWJKSzVyPUG1MlU3OzhizszNM4\TT3NCVkeHUh?=
PANC-08-13Mlz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3vKXGlEPTB;MUWuOlg2QSEQvF2=NIjjbGdUSU6JRWK=
Detroit562M3zKT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkfYTWM2OD1zNT65NVM6KM7:TR?=MYHTRW5ITVJ?
PANC-10-05MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn\tTWM2OD1zNj6wPFIyKM7:TR?=MoTpV2FPT0WU
KOSC-2NFfZU5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MW\JR|UxRTF4LkGxNlUh|ryPMVTTRW5ITVJ?
GT3TKBMVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYDJR|UxRTF4LkG5PFEh|ryPNXXLVo4yW0GQR1XS
KM-H2MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3LpVmlEPTB;MU[uN|Y1PiEQvF2=NVLoSVFsW0GQR1XS
LB771-HNCM1\Qe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXi4[2RPUUN3ME2xOk41PDJ{IN88US=>M4TTSnNCVkeHUh?=
SF268Mm\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{L5PGlEPTB;MU[uOFUzKM7:TR?=NWLBSJpnW0GQR1XS
OE19MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmPZTWM2OD1zNj61NlQh|ryPMYfTRW5ITVJ?
MLMANH7BSJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3j3cWlEPTB;MU[uOVU4OSEQvF2=M4jVd3NCVkeHUh?=
MDA-MB-231MkjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlHDTWM2OD1zNj63NVM3KM7:TR?=M1\wdnNCVkeHUh?=
TGWNXi3XlhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWrJR|UxRTF4LkixNFIh|ryPMlzyV2FPT0WU
MDA-MB-453NEHXTYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M17HUGlEPTB;MUeuNFAxOyEQvF2=M4HOcnNCVkeHUh?=
SNU-C2BNGqxVphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX;JR|UxRTF5LkCyN|ch|ryPNUjJRXA1W0GQR1XS
A427M2Tqc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn7qTWM2OD1zNz6yN|M1KM7:TR?=NVHyO3R2W0GQR1XS
SK-MEL-2M{TNbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVfZ[pZ3UUN3ME2xO{4{OjF|IN88US=>NXXnTIxGW0GQR1XS
KURAMOCHINI[zboRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHHub|RKSzVyPUG3MlM5QTdizszNMlrvV2FPT0WU
IST-MEL1M2XMbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYXJR|UxRTF5LkmxPFIh|ryPMnn4V2FPT0WU
NCI-H1793MljRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGrReZFKSzVyPUG4MlE2QDFizszNNVfsWJhoW0GQR1XS
HCC1395NI[3bnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWXJR|UxRTF6LkW2NVEh|ryPMmL3V2FPT0WU
NUGC-3NX7QWlBjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVLySoI4UUN3ME2xPE43PTh2IN88US=>NIDGW5FUSU6JRWK=
BB65-RCCNYDlXoFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkGyTWM2OD1zOD62Olkh|ryPM2L4WnNCVkeHUh?=
RMG-IMmf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2X6cGlEPTB;MUiuO|M5OiEQvF2=M{LIOnNCVkeHUh?=
LS-513NUXLc|VwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVrJR|UxRTF6LkmyNlgh|ryPM2TYe3NCVkeHUh?=
MFM-223MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHnYXFVKSzVyPUG5MlA4OTZizszNMoX2V2FPT0WU
NCI-H727NWW2cHhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NILleW9KSzVyPUG5MlMzQTVizszNNHj5dpdUSU6JRWK=
KP-4NIP2ToFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlPFTWM2OD1zOT64OVMyKM7:TR?=NGr6ZXJUSU6JRWK=
NB13NXjkeJg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVXRXZN3UUN3ME2xPU45QDN7IN88US=>MXrTRW5ITVJ?
UACC-893M3qwWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGr6dZhKSzVyPUG5Mlk4PTdizszNNEjVZ|hUSU6JRWK=
HT-1197M4Lm[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlzRTWM2OD1{MD6yPVU5KM7:TR?=NF7HUHNUSU6JRWK=
NCI-H2029M4nJbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml\PTWM2OD1{MD6zNlY3KM7:TR?=NUPJb|ExW0GQR1XS
GI-ME-NMWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{juV2lEPTB;MkCuN|M4OyEQvF2=MU\TRW5ITVJ?
OVCAR-3NF\BdmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWPJR|UxRTJyLkW4NlIh|ryPM1PGSHNCVkeHUh?=
HD-MY-ZNV;wblllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYLKe25JUUN3ME2yNU4{Pjl4IN88US=>NXH6fXdbW0GQR1XS
NTERA-S-cl-D1MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX;WN4l6UUN3ME2yNU43PzJ{IN88US=>M3nicHNCVkeHUh?=
SCHNUL5Wm93T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGnkOmVKSzVyPUKyMlQ6PiEQvF2=MlTLV2FPT0WU
KARPAS-299NUftWoE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mo\zTWM2OD1{Mz6zPFg4KM7:TR?=MWfTRW5ITVJ?
NCI-H1650M2fkXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlywTWM2OD1{Mz65NlQyKM7:TR?=MVHTRW5ITVJ?
ACHNNFfHVmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXP4UHR[UUN3ME2yOE41PjV4IN88US=>NHXxcVNUSU6JRWK=
M059JNEn5TY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mk\STWM2OD1{ND61OlM1KM7:TR?=NIrte5JUSU6JRWK=
AM-38M2jIOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWjJR|UxRTJ3LkS4NUDPxE1?M37DU3NCVkeHUh?=
KG-1Mn\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmXhTWM2OD1{NT61OFk1KM7:TR?=NV3BOWh3W0GQR1XS
COLO-824M12xXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml\ZTWM2OD1{NT61OVk6KM7:TR?=Mk\PV2FPT0WU
NCI-H1155MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGixW29KSzVyPUK1MlU5PDdizszNMoPWV2FPT0WU
NCI-H441NX;TfJg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NI\pcYpKSzVyPUK1Mlc1PjVizszNM4jTdXNCVkeHUh?=
J-RT3-T3-5M{XHZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4KzfWlEPTB;Mk[uN|AzPyEQvF2=M4XidXNCVkeHUh?=
JEG-3NUXzUG93T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWnJR|UxRTJ4Lk[4NFUh|ryPM{HhOnNCVkeHUh?=
RKOMVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnvJTWM2OD1{Nj63OlMzKM7:TR?=MoHoV2FPT0WU
CAL-85-1MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3HxdWlEPTB;MkeuNlEyQCEQvF2=NGjhU3pUSU6JRWK=
CAL-120NXnMSVBuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkTqTWM2OD1{Nz62PVE1KM7:TR?=MWrTRW5ITVJ?
NCI-H2452MlnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH:4eohKSzVyPUK3Mlc4OTZizszNMkC5V2FPT0WU
NCI-H1395NVvQWIc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUHJR|UxRTJ5Lke4N|Mh|ryPNXe3ZYJFW0GQR1XS
KYSE-450NGqySolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4P5eWlEPTB;MkeuPVg3OiEQvF2=NUG1W4E2W0GQR1XS
S-117M1fqbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHvFeoJKSzVyPUK5MlM5PTdizszNMnLvV2FPT0WU
SW13M4D2NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVfacIZPUUN3ME2yPU45PTF7IN88US=>M{PpSnNCVkeHUh?=
ES3NX\LNZU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkLZTWM2OD1|MD6zO|M{KM7:TR?=MmPHV2FPT0WU
HCT-116M4LaNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVvRTmpwUUN3ME2zNE42PTV2IN88US=>NIWzdINUSU6JRWK=
NCI-H1693MoXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV\JR|UxRTNyLkW5OFIh|ryPM4jKSnNCVkeHUh?=
VM-CUB-1M1Oyd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV;JR|UxRTNyLk[0NVMh|ryPNXzkZ3dlW0GQR1XS
NCI-H2170M{TvNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGfLOWJKSzVyPUOxMlU4QDRizszNNXnyeIhDW0GQR1XS
ALL-POMlzSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4jwdGlEPTB;M{GuPFQzQCEQvF2=MkS3V2FPT0WU
NCI-H661MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3\CSmlEPTB;M{KuNFYzOyEQvF2=NHPS[FVUSU6JRWK=
NCI-H2347MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUPJR|UxRTN{LkS4N|ch|ryPMXHTRW5ITVJ?
FTC-133NWTlVox5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1rvVmlEPTB;M{KuO|A3KM7:TR?=MVnTRW5ITVJ?
COLO-829M2jxcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYe5OXpNUUN3ME2zN{4{PDZ5IN88US=>MUnTRW5ITVJ?
GOTOM4fH[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXHJR|UxRTN|LkWyOVgh|ryPM1rxTXNCVkeHUh?=
YAPCNWXIeHprT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEPvc5RKSzVyPUOzMlgyPTlizszNMX;TRW5ITVJ?
LCLC-103HM{LLWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M33wRWlEPTB;M{SuNVYzPCEQvF2=NWLVfoVsW0GQR1XS
SiHaNHHaPYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXnv[IVHUUN3ME2zOE4{QDF5IN88US=>MWrTRW5ITVJ?
LK-2M3\HVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoDTTWM2OD1|ND61O|A5KM7:TR?=NWfjRmxDW0GQR1XS
KP-N-YSNGLpWppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVezUXFDUUN3ME2zOE44OjB{IN88US=>M{\SdXNCVkeHUh?=
NCI-SNU-1NGTtdnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGPiPGNKSzVyPUO1MlE4QSEQvF2=NWjuO2hPW0GQR1XS
KNS-81-FDNVixV2ZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWDvSllTUUN3ME2zOU43PjNizszNMmfOV2FPT0WU
SCC-9M1PvXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2PPTGlEPTB;M{[uO|E1PiEQvF2=M2HYPXNCVkeHUh?=
SH-4M1;NZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnLCTWM2OD1|Nj63N{DPxE1?M4L5RXNCVkeHUh?=
HCC-1954MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2HRR2lEPTB;M{euNlczQSEQvF2=NIXqbWJUSU6JRWK=
BALL-1M3v0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3vqVmlEPTB;M{euOVMyPiEQvF2=MmW5V2FPT0WU
BE-13NUnGdW9kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWXJR|UxRTN5LkewNVgh|ryPNHW0THpUSU6JRWK=
COLO-678Mkj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWD0dZJXUUN3ME2zO{46PDN5IN88US=>MU\TRW5ITVJ?
SK-MEL-3Ml;2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUHJR|UxRTN6LkKzPVch|ryPMmqwV2FPT0WU
OAW-28NGXKN3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYXNN4pyUUN3ME2zPE43OzlizszNNUnSPYhWW0GQR1XS
CAMA-1M{nRcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYPHXIp6UUN3ME2zPE46PjlzIN88US=>M{PRXnNCVkeHUh?=
C2BBe1M13kfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3zxfWlEPTB;M{muPFE5KM7:TR?=NHmxdoZUSU6JRWK=
A3-KAWM3WzdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn:5TWM2OD12MD6zOlYyKM7:TR?=MVPTRW5ITVJ?
SK-MEL-24MkTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2\x[mlEPTB;NECuOVk{OSEQvF2=NETnbGlUSU6JRWK=
KYSE-140MmG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml[5TWM2OD12MD63NVY2KM7:TR?=NV\0WodvW0GQR1XS
MOLT-16NH3lUWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnfXTWM2OD12MT6xOVM3KM7:TR?=NWm1NnhNW0GQR1XS
CFPAC-1NIDwdndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYXJR|UxRTR{LkWyNVEh|ryPM2jO[XNCVkeHUh?=
NB14NV\Qb3M1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFvtS4xKSzVyPUSyMlcxOjdizszNM4n4eHNCVkeHUh?=
COLO-792NF[wd5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnTWTWM2OD12Mj64PVYyKM7:TR?=MmPIV2FPT0WU
RH-1MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3XzWmlEPTB;NEOuOFg{PiEQvF2=M1Hu[XNCVkeHUh?=
NCI-H522NFjJdJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{XJUWlEPTB;NESuN|U3QCEQvF2=MYnTRW5ITVJ?
Ca-SkiNFG1NFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWfJR|UxRTR2LkixNVQh|ryPMoT0V2FPT0WU
KGNMV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXLHN5I2UUN3ME20PE4{ODZ|IN88US=>NUTITmp1W0GQR1XS
UACC-62NUDGSI43T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUfFUHpkUUN3ME20PE41ODd{IN88US=>MojyV2FPT0WU
NCI-H358MnPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYLJR|UxRTR7LkOwNVgh|ryPM2[2fHNCVkeHUh?=
LS-411NMnezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHvUfHRKSzVyPUS5MlMyOThizszNNUjQdmE3W0GQR1XS
IST-MES1M{LCemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkDnTWM2OD12OT61OlI2KM7:TR?=NIfablZUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Administration of GDC-0941 at 75 mg/kg/day displays significant inhibitory effect against established human U87MG glioblastoma xenografts in female NCr athymic mice, with tumor growth inhibition of 83%. [1] Oral administration of GDC-0941 at 150 mg/kg/day inhibits the growth of HER2-amplified, trastuzumab-resistant MDA-MB-361.1 xenografts in mice, and significantly delays the tumor progression, in association with potent induced apoptosis in tumors. [2] GDC-0941 (75 mg/kg/day) treatment for 2 weeks induces ~40% reduction in tumor volume of spontaneous B-cell follicular lymphomas developed in PTEN+/-LKB1+/hypo mice, accompanied by ablation of phosphorylation of Akt, S6K and SGK (serum and glucocorticoid protein kinase) protein kinases. [4]
Features

Protocol(Only for Reference)

Kinase Assay: [1]

Scintillation proximity assay Recombinant human PI3Kα, PI3Kβ, and PI3Kδ are coexpressed in a Sf9 baculovirus system with the p85α regulatory subunit and purified as GST-fusion proteins using affinity chromatography on glutathione-sepharose. Recombinant human PI3Kγ is expressed as monomeric GST-fusions and purified similarly. GDC-0941 is dissolved in DMSO and added to 20 mM Tris-HCl (pH 7.5) containing 200 μg yttrium silicate (Ysi) polylysine SPA beads, 4 mM MgCl2, 1 mM dithiothreitol (DTT), 1 μM ATP, 0.125 μCi [γ-33P]-ATP, and 4% (v/v) DMSO in a total volume of 50 μL. The recombinant GST-fusion of PI3Kα (5 ng), PI3Kβ (5 ng), PI3Kδ (5 ng), or PI3Kγ (5 ng) is added to the assay mixture to initiate the kinase reaction. After incubation for 1 hour at room temperature, the kinase reaction is terminated with 150 μL PBS. The mixture is then centrifuged for 2 minutes at 2000 rpm and read using a Wallac Microbeta counter. The reported IC50 values are calculated using a sigmoidal, dose-response curve fit in MDL Assay Explorer.

Cell Assay: [2]

Cell lines SKBR-3, BT474-M1, AU-565, HCC-1419, ZR75-30, KPL-4, JIMT-1, BT474-EEI, HCC-1954, MCF-7, CALU-3, SKOV-3, and MKN-7 cells
Concentrations Dissolved in DMSO, final concentrations ~10 μM
Incubation Time 48 and 72 hours
Method Cells are exposed to various concentrations of GDC-0941 for 48, and 72 hours. Proliferation/viability of cells is detected by using the CellTiter-Glo Luminescent Cell Viability Assay. The pAkt (Ser473), cleaved caspase-3, and cleaved PARP are analyzed by western blot. The Caspase-Glo 3/7 assay and the Cell Death Detection ELISAplus assay are used to detect caspase 3/7 activity, and apoptosis, respectively.

Animal Study: [2]

Animal Models NCR nude mice implanted with MDA-MB-361.1 cells, and SCID, C.B-17/IcrHsd-Prkdcscid mice implanted subcutaneously with BT474-M1 cells
Formulation Dissolved in 10% DMSO, 5% Tween 20, 85% water
Dosages ~150 mg/kg/day
Administration Oral gavage

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Folkes AJ, et al. J Med Chem, 2008, 51(18), 5522-5532.

[2] Junttila TT, et al. Cancer Cell, 2009, 15(5), 429-440.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-23)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02092831 Completed Healthy Volunteer Genentech, Inc. April 2014 Phase 1
NCT01740336 Active, not recruiting Breast Cancer Genentech, Inc. February 2013 Phase 2
NCT01493843 Completed Non-Squamous Non-Small Cell Lung Cancer Genentech, Inc. January 2012 Phase 2
NCT01437566 Completed Breast Cancer Genentech, Inc. October 2011 Phase 2
NCT01474668 Completed Healthy Volunteer Genentech, Inc. October 2011 Phase 1

view more

Chemical Information

Download Pictilisib (GDC-0941) SDF
Molecular Weight (MW) 513.64
Formula

C23H27N7O3S2

CAS No. 957054-30-7
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms RG7321
Solubility (25°C) * In vitro DMSO 44 mg/mL (85.66 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 2% DMSO+30% PEG 300+5% Tween 80+ddH2O 5mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 2-(1H-indazol-4-yl)-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinothieno[3,2-d]pyrimidine

Customer Product Validation(7)


Click to enlarge
Rating
Source Cancer Res 2011 71, 2750-2760. Pictilisib (GDC-0941) purchased from Selleck
Method Western blot, Immunofluorescence staining, flow cytometry
Cell Lines 1205Lu cells
Concentrations 3 µmol/L
Incubation Time 48 h
Results Combined PI3K and BRAF inhibition increased the level of BIM expression in both Western blot and immunofluorescence studies (Fig. A). Consistent with a role for increased AKT signaling suppressing BIM expression in PTEN- cells, dual BRAF and PI3K inhibition increased nuclear FOXO3a localization in the PTEN- cell lines (Fig. B) and enhanced the level of BIM mRNA (Fig. B). the combination of PLX4720 with the PI3K inhibitor GDC-0941 significantly enhanced the levels of apoptosis observed in PTEN melanoma cell lines compared to either the BRAF or PI3K inhibitor alone (Fig. C). Similar results were also observed in a 3D spheroid assay, where combined PLX4720 (3 µmol/L) and LY294002 (10 µmol/L) treatment prevented the recovery of cell growth observed when melanoma spheroids were treated with either drug alone (Fig. D).

Click to enlarge
Rating
Source J Inves Der 2010 131, 495-503. Pictilisib (GDC-0941) purchased from Selleck
Method Western blot
Cell Lines Mel-Juso cells, 518A2 cells
Concentrations 0.05–1 µmol/L
Incubation Time 24 h
Results In addition, GDC-0941 treatment blocked the phosphorylation of AKT protein (S473 and T308) at even lower concentrations than PI-103, and S6 protein phosphorylation was blocked at similar concentrations.

Click to enlarge
Rating
Source J Cell Sci 2012 125(Pt 5), 1259-73. Pictilisib (GDC-0941) purchased from Selleck
Method Western Blot
Cell Lines NMuMG cells
Concentrations 1 μM
Incubation Time 1 h
Results GDC-0941, a specific inhibitor of the class IA PI3K, similarly blocked the TGF-b-induced Akt(S473) phosphorylation, confirming the role of PI3K in the induction of mTORC2 kinase activity by TGF-β (Fig. C).

Click to enlarge
Rating
Source Biochim Biophys Acta 2012 1823, 2210-6. Pictilisib (GDC-0941) purchased from Selleck
Method confocal laser-scanning microscopy
Cell Lines HEK293 cells
Concentrations 1 μM
Incubation Time 30 min
Results Both LY294002 and GDC-0941 markedly attenuated the high-glucose-dependent plasma membrane translocation of DGKδ1, indicating that the event is positively regulated by phosphatidylinositol 3-kinase.

Click to enlarge
Rating
Source Dr. Zhang of Tianjin Medical University. Pictilisib (GDC-0941) purchased from Selleck
Method Western blot
Cell Lines Breast cancer cells
Concentrations 0-10 nM
Incubation Time 3 h
Results

Click to enlarge
Rating
Source Saraswati Sukumar of Johns Hopkins University School of Medicine. Pictilisib (GDC-0941) purchased from Selleck
Method Western blot
Cell Lines T47D cells
Concentrations
Incubation Time 1 h
Results

Click to enlarge
Rating
Source Pictilisib (GDC-0941) purchased from Selleck
Method Western blot analysis
Cell Lines MCF-7 cells
Concentrations 0 nM/50 nM/100 nM/400 nM
Incubation Time 24 h
Results GDC-0941 caused a surprising increase in phosphorylation of ERK proteins as well as AKT2 S474. GDC-0941 showed differences in its ability to suppr ess PI3K-dependent signaling across the genotypes. AKT1 mutant cells demonstrated greater residual AKT1 S473 phosphorylation and greater phosphorylation of downstream proteins FOXO 1/3, PRAS40, GSK3β , and p70S6K at equivalent doses of GDC-0941, compared to PIK3CA mutant cells.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related PI3K Products

  • GDC-0032

    GDC-0032 is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with Ki of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

    Features:A beta isoform-sparing PI3K inhibitor.

  • Pilaralisib (XL147)

    Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.

  • GNE-317

    GNE-317 is a potent, brain-penetrant PI3K inhibitor.

  • LY294002

    LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM in cell-free assays, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation.

  • 3-Methyladenine (3-MA)

    3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation.

  • CAL-101 (Idelalisib, GS-1101)

    CAL-101 (Idelalisib, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR.

  • Wortmannin

    Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.

  • BEZ235 (NVP-BEZ235, Dactolisib)

    BEZ235 (NVP-BEZ235, Dactolisib) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3TopBP1-ER cell.

  • BKM120 (NVP-BKM120, Buparlisib)

    BKM120 (NVP-BKM120, Buparlisib) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2.

  • Alpelisib (BYL719)

    Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Recently Viewed Items

Tags: buy Pictilisib (GDC-0941) | Pictilisib (GDC-0941) supplier | purchase Pictilisib (GDC-0941) | Pictilisib (GDC-0941) cost | Pictilisib (GDC-0941) manufacturer | order Pictilisib (GDC-0941) | Pictilisib (GDC-0941) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us